Cipla cuts prices of 3 cancer drugs by up to 64%
Lung cancer drug Erlocip would cost `9,900 for 30 tablets, while breast cancer treatment Docetax would be priced at `1,650
Cipla Ltd cut prices of three cancer drugs between 50% and 64% with immediate effect, after it announced similar price cuts for three drugs early this year.
Lung cancer drug Erlocip would cost ₹ 9,900 for 30 tablets instead of ₹ 27,000 earlier, while breast cancer treatment Docetax would be priced ₹ 1,650 instead of ₹ 3,300, Cipla said in a statement on Thursday.
Cipla last month won a case against Roche Holding AG, which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.
Capegard, another drug to treat metastatic colorectal and colon caner, would be priced ₹ 600 for 10 tablets instead of ₹ 1,200, it said.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!